Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?

Affiliations

• ¹ Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
• ² Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia.
• ³ Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
• ⁴ Genesis Cancer Care, Sydney, New South Wales, Australia.
• ⁵ Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.
• ⁶ Genesis Care, Maitland, Metford, New South Wales, Australia.
• ⁷ Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia.
• ⁸ Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
• ⁹ Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
• ¹⁰ Department of Surgery, Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
• ¹¹ Cabrini Research, Cabrini Health, Melbourne, Victoria, Australia.
• ¹² Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
• ¹³ St Vincent's Hospital, Darlinghurst, Sydney, New South Wales, Australia.
• ¹⁴ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Victoria, Melbourne, Australia.
• ¹⁵ Eastern Health Clinical School, Monash University, Victoria, Melbourne, Australia.
• ¹⁶ Department of Cancer Services, Eastern Health, Melbourne, Victoria, Australia.
• ¹⁷ Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
• ¹⁸ Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.